Factors associated with choice of biologic among children with Juvenile Idiopathic Arthritis: Results from two UK paediatric biologic registers

Rheumatology (United Kingdom)

Volumn 55, Issue 9, 2016, Pages 1556-1565

  Kearsley Fleet, Lianne ^a   Davies, Rebecca ^a   Baildam, Eileen ^b   Beresford, Michael W ^b,c   Foster, Helen E ^d   Southwood, Taunton R ^e   Thomson, Wendy ^a,f   Hyrich, Kimme L ^a,f  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b Clinical Academic Department of Paediatric Rheumatology   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^f MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Attitude of health professionals; Biological therapies; Epidemiology; Information science; Juvenile idiopathic arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; BIOLOGICAL PRODUCT; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; BIOLOGICAL FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MONOCLONAL ANTIBODY;

ADOLESCENT; ARTICLE; BIOLOGICAL THERAPY; CHILD; CORTICOSTEROID THERAPY; DISEASE DURATION; FEMALE; HUMAN; IRIDOCYCLITIS; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PRESCRIPTION; PRIORITY JOURNAL; UNITED KINGDOM; ARTHRITIS, JUVENILE; CLINICAL DECISION MAKING; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG SUBSTITUTION; MULTICENTER STUDY; PRESCHOOL CHILD; PROSPECTIVE STUDY; REGISTER;

ADALIMUMAB; ADOLESCENT; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, JUVENILE; BIOLOGICAL FACTORS; CHILD; CHILD, PRESCHOOL; CLINICAL DECISION-MAKING; DRUG SUBSTITUTION; FEMALE; HUMANS; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; PROSPECTIVE STUDIES; REGISTRIES;

EID: 84995666147     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kev429     Document Type: Article

References (38)

1. Symmons DP, Jones M, Osborne J et al. Pediatric rheumatology in the United Kingdom: data from the British Pediatric Rheumatology Group National Diagnostic Register. J Rheumatol 1996;23:1975-80.
2. Petty RE, Southwood TR, Manners P et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001 J Rheumatol 2004;31:390-2.
3. European Medicines Agency/Committee for Medicinal Products for Human Use. Enbrel. Summary of opinion (post authorisation). 2012. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000262/human_med_000764.jsp&mid= WC0b01ac058001d124 (5 May 2015, date last accessed).
4. National Institute for Health and Care Excellence. Guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis. 2002. https://www.nice.org.uk/guidance/ta35 (1 December 2015, date last accessed).
5. National Institute for Health and Care Excellence. Tocilizumab for the treatment of systemic juvenile idiopathic arthritis. 2011. https://www.nice.org.uk/Guidance/TA238 (30 November 2015, date last accessed).
6. Otten MH, Anink J, Prince FH et al. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register. Ann Rheum Dis 2014;74:1379-86.
7. Alexeeva EI, Valieva SI, Bzarova TM et al. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. Clin Rheumatol 2011;30:1163-72.
8. Kasher-Meron M, Uziel Y, Amital H. Successful treatment with B-cell depleting therapy for refractory systemic onset juvenile idiopathic arthritis: a case report. Rheumatology 2009;48:445-6.
9. De Benedetti F, Brunner HI, Ruperto N et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2385-95.
10. Quartier P, Allantaz F, Cimaz R et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011;70:747-54.
11. Beukelman T. Treatment advances in systemic juvenile idiopathic arthritis. F1000prime Rep 2014;6:21
12. Ruperto N, Brunner HI, Quartier P et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2396-406.
13. Ramanan AV, Dick AD, Benton D et al. A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial). Trials 2014;15:14.
14. Smith EM, Foster HE, Beresford MW. The development and assessment of biological treatments for children. Br J Clin Pharmacol 2014;79:379-94.
15. Otten MH, Prince FH, Anink J et al. Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register. Ann Rheum Dis 2013;72:721-7.
16. Giannini EH, Ruperto N, Ravelli A et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9.
17. Vastert SJ, de Jager W, Noordman BJ et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol 2014;66:1034-43.
18. Quartier P, Taupin P, Bourdeaut F et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003;48:1093-101.
19. Ravelli A, Grom AA, Behrens EM, Cron RQ. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immunity 2012;13:289-98.
20. Kelly A, Ramanan AV. A case of macrophage activation syndrome successfully treated with anakinra. Nature clinical practice. Rheumatology 2008;4:615-20.
21. Bruck N, Suttorp M, Kabus M et al. Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids. J Clin Rheumatol 2011;17:23-7.
22. Miettunen PM, Narendran A, Jayanthan A, Behrens EM, Cron RQ. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology 2011;50:417-9.
23. Anink J, Otten MH, Gorter SL et al. Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab? Rheumatology 2013;52:1674-9
24. Kahn P, Weiss M, Imundo LF, Levy DM. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology 2006;113:860-4.e2.
25. Richards JC, Tay-Kearney ML, Murray K, Manners P. Infliximab for juvenile idiopathic arthritis-associated uveitis. Clin Exp Ophthalmol 2005;33:461-8.
26. Saurenmann RK, Levin AV, Rose JB et al. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology 2006;45:982-9.
27. Tynjala P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007;66:548-50.
28. Smith JA, Thompson DJ, Whitcup SM et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005;53:18-23.
29. Southwood TR, Foster HE, Davidson JE et al. Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients. Rheumatology 2011;50:189-95.
30. Garcia-De-Vicuna C, Diaz-Llopis M, Salom D et al. Usefulness of adalimumab in the treatment of refractory uveitis associated with juvenile idiopathic arthritis. Mediators Inflamm 2013;2013:560632.
31. Kotaniemi K, Saila H, Kautiainen H. Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis. Clin Ophthalmol 2011;5:1425-9.
32. Ostring GT, Singh-Grewal D. Juvenile idiopathic arthritis in the new world of biologics. J Paediatrics Child Health 2013;49:E405-12.
33. Tynjala P, Kotaniemi K, Lindahl P et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology 2008;47:339-44.
34. Magli A, Forte R, Navarro P et al. Adalimumab for juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol 2013;251:1601-6.
35. Horneff G. Update on biologicals for treatment of juvenile idiopathic arthritis. Expert Opin Biol Ther 2013;13: 361-76.
36. ClinicalTrials.gov. Effect of adalimumab for the treatment of uveitis in juvenile idiopathic arthritis (ADJUVITE). 2015. https://www.clinicaltrials.gov/ct2/show/NCT01385826 (27 October 2015, date last accessed).
37. Schmeling H, Minden K, Foeldvari I et al. A38: Twelve years' experience with etanercept in the treatment of juvenile idiopathic arthritis: how it has changed practice-the German Biologics JIA Registry (BiKeR). Arthritis Rheum 2014;66:S58.
38. Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.